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Abstract
Background: The mucin MUC1, a type I transmembrane glycoprotein, is overexpressed in breast cancer and has
been correlated with increased metastasis. We were the first to report binding between MUC1 and Intercellular
adhesion molecule-1 (ICAM-1), which is expressed on stromal and endothelial cells throughout the migratory tract
of a metastasizing breast cancer cell. Subsequently, we found that MUC1/ICAM-1 binding results in pro-migratory
calcium oscillations, cytoskeletal reorganization, and simulated transendothelial migration. These events were found
to involve Src kinase, a non-receptor tyrosine kinase also implicated in breast cancer initiation and progression.
Here, we further investigated the mechanism of MUC1/ICAM-1 signalling, focusing on the role of MUC1
dimerization in Src recruitment and pro-metastatic signalling.
Methods: To assay MUC1 dimerization, we used a chemical crosslinker which allowed for the detection of dimers
on SDS-PAGE. We then generated MUC1 constructs containing an engineered domain which allowed for
manipulation of dimerization status through the addition of ligands to the engineered domain. Following
manipulation of dimerization, we immunoprecipitated MUC1 to investigate recruitment of Src, or assayed for our
previously observed ICAM-1 binding induced events. To investigate the nature of MUC1 dimers, we used both
non-reducing SDS-PAGE and generated a mutant construct lacking cysteine residues.
Results: We first demonstrate that the previously observed MUC1/ICAM-1signalling events are dependent on the
activity of Src kinase. We then report that MUC1 forms constitutive cytoplasmic domain dimers which are
necessary for Src recruitment, ICAM-1 induced calcium oscillations and simulated transendothelial migration. The
dimers are not covalently linked constitutively or following ICAM-1 binding. In contrast to previously published
reports, we found that membrane proximal cysteine residues were not involved in dimerization or ICAM-1 induced
signalling.
Conclusions: Our data implicates non-cysteine linked MUC1 dimerization in cell signalling pathways required for
cancer cell migration.
Background
The ability of malignant cells to escape from a primary
tumour mass and migrate to distal sites to form meta-
static tumors is the cause of mortality in the majority of
carcinomas, including breast carcinoma. Approximately
20% of breast cancers belong to the Luminal B genetic
subtype, typified by estrogen receptor positivity and a
slow, steady rate of recurrence over time despite anti-
estrogen therapy [1]. Estrogen is known to increase the
expression of MUC1 [2], a well-characterized member
of the mucin family of glycoproteins, and a correlation
has been demonstrated between MUC1 expression,
resistance to anti-estrogen therapy and metastatic beha-
viour [3]. We have been investigating the mechanism of
cell migration in the Luminal B breast cancer cell lines
MCF7 and T47D, and were the first to demonstrate that
MUC1 mediates heterotypic cell-cell adhesion by bind-
ing ICAM-1 [4], which is expressed on peritumoral stro-
mal and endothelial cells. Subsequently, we
demonstrated that ICAM-1 binding triggers calcium
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any medium, provided the original work is properly cited.oscillations which may activate proteins involved in focal
adhesion disassembly and cell contraction. In keeping
with this, we further reported that after interaction with
ICAM-1, transendothelial migration invasion in MUC1
expressing cells is associated with increased MUC1-Src
association, MUC1-cytoplasmic domain (MUC1-CD)
phosphorylation, CrkL recruitment, and Rho-GTPase
mediated cytoskeletal rearrangement [5-7].
MUC1 (also known as DF3, CA15-3, or episialin) is
expressed apically on normal breast epithelia, but often
loses this polarization and becomes underglycosylated in
breast cancer [8,9]. MUC1 is translated as a single poly-
peptide, followed by conformational stress-induced clea-
vage resulting in a heterodimer of non-covalently
associated extracellular and cytoplasmic portions [10,11]
(Figure 1). The extracellular portion consists of a vari-
able number of 20-amino acid (aa) tandem repeats con-
taining multiple sites for O-glycosylation, which impart
a negative charge and result in a structure that can
extend up to 500 nm from the cell surface. The cyto-
plasmic portion consists of a 58-aa extracellular stub, a
28-aa transmembrane domain, and a 72-aa cytoplasmic
domain, which contains seven conserved tyrosine resi-
dues, and has been shown to interact with diverse effec-
tors [Reviewed in [12]] which is important since MUC1-
CD itself lacks tyrosine kinase activity.
The signalling capacity of transmembrane proteins
lacking kinase activity is often mediated by associated
non-receptor tyrosine kinases. In some instances, these
kinases are bound to pre-formed dimers of the receptor
[[13], Reviewed in [14]]. Upon ligand binding, structural
changes such as cysteine linkage, association with deter-
gent resistant membrane fractions, and changes in clea-
vage result in signal initiation [15-17]. Previous work by
others has demonstrated that constructs of the MUC1-
CD form oligomers in vitro which are disulfide-linked,
and in vivo which are dependent on the membrane-
proximal cytoplasmic C
1QC motif [18,19] (Figure 1).
Here, we investigated dimer formation in wild-type
MUC1 and the relationship between dimerization, Src
recruitment and ICAM-1 induced signalling events. We
also examined the role of membrane-proximal cytoplas-
mic domain cysteine residues in these phenomena. We
confirm that Src is an essential mediator of the pre-
viously observed ICAM-1 binding pro-motility events
and show that MUC1 forms constitutive cytoplasmic
domain dimers which are required for constitutive Src
recruitment and ICAM-1 binding induced signalling.
Contrary to previous reports, we found that dimers are
not disulfide linked constitutively or following ICAM-1
ligation, and that membrane-proximal cysteine residues
are not required for dimerization or ICAM-1 induced
events.
Materials and methods
Antibodies and Reagents
CT2 Armenian Hamster monoclonal antibody (mAb)
[20], directed against the last 17 C-terminal amino acids
of MUC1-CD, was generously provided by Dr. Sandra
Gendler (Mayo Clinic, Scottsdale, AZ). Rabbit anti-Src
mAb, anti-Src
P416 polyclonal Abs, and anti-rabbit perox-
idase conjugated secondary antibody were purchased
from Cell Signalling. Goat anti-mouse and anti-Arme-
nian hamster peroxidase-conjugated secondary antibo-
dies were purchased from Jackson ImmunoResearch
Laboratories, Inc. Mouse anti-tubulin antibody was from
Sigma-Aldrich. Disuccinimidyl suberate (DSS) was from
PierceNet. Protein G-Agarose was purchased from
Roche Diagnostics. ECL Plus Western Blotting detection
reagent was purchased from GE Healthcare (Amersham
Biosciences). Gelatin Type A and phosphatase inhibitor
cocktail were from Sigma-Aldrich. Protease inhibitor
Figure 1 Schematic of constructs used in this study. “SS” indicates signal sequence, “ECD” indicates extracellular domain, “TMD” indicates
transmembrane domain and “CD” indicates cytoplasmic domain. On SDS-PAGE, full-length MUC1 dissociates at “cleavage site” and runs as two
separate entities.
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eagle media (DMEM), fetal bovine serum (FBS), Lipofec-
tamine 2000, G418, Blasticidin S HCl, Pluronic F-127,
Fluo-3 and Cell Tracker Green CMFDA were from Invi-
trogen. AP20187
D and AP21998
M were generous gifts
from ARIAD Pharmaceuticals, Inc (Cambridge, MA,
USA).
Plasmid construction
The pC1-Neo-hMUC1-TR+ plasmid was kindly pro-
vided by Dr. Sandra Gendler. The pUC-CVM-MUCY
plasmid was from Gene-Therapeutics Luckenwalde
(Luckenwalde, Germany). MUC1-CFP and MUCY-YFP
were constructed by inserting the MUC1/MUCY genes
into pECFP/pEYFP plasmids (ClonTech) respectively, at
XhoI and SacII sites. The plasmid pC4-Fv1E encoding
the FKBP F36V variant followed by a c-terminal hemag-
glutinin (HA) epitope was generously provided by
ARIAD Pharmaceuticals Inc. To generate the MUC1-
CFP-FvHA and MUCY-YFP-FvHA fusion proteins, the
FvHA domain of pC4-Fv1E was amplified by polymerase
chain reaction (PCR) with a 5’ primer (ATTTGTA-
CATGGCTTCTAGAGGAGTGC) and a 3’ primer
(CTCTTGTACACTGAAGTTCTCAGGATCC) which
introduced 3’ and 5’ BsrG1 restriction sites (underlined).
The PCR product and MUC1-CFP/MUCY-YFP plasmids
were digested with BsrG1, ligated, and sequenced to
confirm insertion and orientation. MUC1-CFP-FvHA
(CQC to AQA) was constructed by PCR of MUC1-CFP
using overlapping forward (TTGGCTGTCGCT
CAGGCCCGCCGAAAG) and reverse (CTTTCGGC
GGGCCTGAGCGACAGCCAA) primers to generate
the mutation (underlined) and upstream (GGC
ACCTCTGCCAGGGCTACCACAACC) and down-
stream (GACCGGTGGATCCCGGGCCCG) primers
containing EcoN1 and BamH1 restriction sites, respec-
tively (underlined). Digestion of plasmid and PCR pro-
duct with EcoN1 and BamH1 was followed by ligation
of the plasmid backbone and mutated insert and
sequencing to confirm insert. The pcDNA3.1-CD8/
MUC1 plasmid was kindly provided by Dr. K.C. Kim
(Lovelace Respiratory Research Institute, AZ), and
encodes a construct containing the extracellular and
transmembrane portions of cluster of differentiation 8
(CD8) and MUC1-CD, beginning at R
4RK (Figure 1).
Cell culture
Human breast cancer cell lines T47D and MCF-7 were
from the American Type Culture Collection (ATCC)
and were maintained in DMEM with 10% FBS and 6
ug/ml insulin. 293T human embryonic kidney epithelial
cells (293T HEK) were from ATCC and maintained in
DMEM with 10% FBS. Mock and ICAM-1 transfected
NIH 3T3 mouse fibroblast cells were a generous gift of
Dr. Ken Dimock (University of Ottawa, Ontario,
Canada) and were maintained in DMEM with 10% FBS
and 5 ug/ml Blasticidin S. HEK 293T cells transfected
with MUC1 constructs were maintained in DMEM with
10% FBS and 200 ug/ml G418 and used for experiments
within 48 hours of transfection. Cell lines have not been
further tested or authenticated.
Small interfering ribonucleic acid (siRNA) knockdown
4×1 0
5 HEK 293T cells were plated in a 6-well plate
and allowed to adhere overnight to approximately 50%
confluency. siRNA (Dharmacon) consisted of four
pooled siRNA species targeting the following Src
sequences: GCAGUUGUAUGCUGUGGUU, GCAGA-
GAACCCGA GAGGGA, CCAAGGGCCUCA ACGU-
GAA, and GGGAGAACCUCUAGGCACA. Transfection
was performed using Lipofectamine 2000 (Invitrogen),
according to the manufacturer’s instructions. Lipofecta-
mine reagent only or non-targeting siRNA were used as
negative controls.
Dimer detection
To detect constitutive dimers, we added a cross-linking
agent before lysis to parallel cultures and analyzed by
Western blot as follows. 3 × 10
6 human breast cancer
cells or transfected HEK 293T cells were plated on 0.1%
gelatin coated, UV-treated 10 cm dishes and allowed to
adhere overnight. Cells were then serum starved for 45
minutes in Imaging Buffer (152 mM NaCl, 5.4 mM KCl,
0.8 mM MgCl2 6H2O, 1.8 mM CaCl2 2H2O, 10 mM
HEPES, 5.6 mM D-glucose). Treatment compounds or
cell suspensions were then added as indicated, in 37°C
Imaging buffer, followed by 1 mM DSS in ice-cold PBS
for 10 minutes. DSS is a membrane-permeable, perma-
nent crosslinker which targets primary amine residues
(lysines) within 11.4 Å of eachother. DSS does not
induce dimerization of lysine-containing proteins, but
rather aids in identification of protein complexes which
are already formed upon treatment. DSS was aspirated,
cells resuspended in quenching solution (1M Tris, pH
7.5) and centrifuged. The pellet was suspended in ice-
cold lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM
NaCl, 2 mM EDTA, 1% glycerol, 1% Triton X-100, 0.5%
phosphatase and protease inhibitors) or Co-immunopre-
cipitation lysis buffer (50 mM Tris pH 7.6, 100 mM
NaCl, 0.5 mM EDTA, 0.5% Nonidet P-40, 0.5% protease
and phosphatase inhibitors). Lysates were immunopreci-
pitated with CT2 and/or prepared for Western blot ana-
lysis as described below.
Dimer manipulation
To artificially manipulate MUC1-CD dimerization we
used the “ARGENT™ Regulated homodimerization kit”
and the “RPD™ Regulated secretion/aggregation kit”
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manipulate protein dimerization status by interacting an
engineered “Fv dimerization domain” with monovalent
and bivalent ligands. The “Fv domain” is a mutant of
the naturally occurring FK506 binding protein (FKBP)
with a F36V mutation introduced to prevent binding of
Fv ligands to endogenous FKBP. A MUC1-CFP-Fv con-
struct was creating using this plasmid, as described
above. Importantly, the Fv domain itself does not induce
dimerization, and addition of Fv domain ligands is
required to manipulate dimerization status of Fv domain
containing proteins. The bivalent Fv ligand AP20187
D
was designed to induce dimerization of Fv domain con-
taining proteins, while the monovalent Fv ligand
AP21998
M was designed to disaggregate existing dimers.
Immunoprecipitation and Western blots
Lysates were immunoprecipitated, prepared for SDS-
PAGE, and probed for proteins of interest as described
in [6]. Films were scanned with a Canon Canoscan
8 6 0 0 F ,i m p o r t e di n t oI m a g eJ( N I H ) ,c o n t r a s ta n d
brightness adjusted and cropped for presentation.
Calcium oscillation assay
Calcium oscillation assay was performed and analyzed as
described [5]. Modifications included the treatment of
cells with 1 uM AP21998
M or AP20187
D for 1 minute
prior to addition of NIH ICAM-1 cells, and the use of
Eclipse software to obtain digital interference contrast
(DIC) and fluorescent images.
Transwell migration assay
The upper membrane of Transwell inserts (Corning
Costar, 6.5 mm diameter, 8 μm pore size) coated with
0.1% gelatin and 200 ul of ICAM-1/mock cell suspension
at 1.5 × 10
5 cells/ml was placed in a 24-well plate and
allowed to adhere overnight at 37°C. 293T MUC1 trans-
fectants were suspended in 5 uM Cell tracker green in
serum-free DMEM for 30 minutes at 37°C, followed by
incubation in serum free DMEM at 37°C for 30 minutes.
Cells were spun and suspended in serum-free media at 8
×1 0
5 cells/ml. 1 uM AP21998
M or AP20187
D was added
and 200 ul of cell suspension was added to the upper
membrane of Transwell inserts. Fresh serum-free DMEM
was added to the lower chamber. Following incubation at
37°C overnight, media was removed and 2% paraformal-
dehyde in PBS was added to each chamber for 15 min-
utes. Cells were washed twice with PBS, and cells on the
upper membrane of the insert were removed with a ster-
ile cotton swab. The insert was then placed under a Zeiss
Axioscope Digital Imaging Microscope and cells on the
lower side of the chamber were counted under a fluores-
cein isothiocyanate filter and 20× objective for five dis-
tinct fields of view.
Statistics
All experiments were performed at least three times to
allow for statistical analysis. The Newman-Keuls multi-
ple range comparison was used to determine statistical
differences in data sets with more than two experimen-
tal conditions. For pairwise comparisons, the Student’s t
test was used. P values are indicated for each analysis.
For each experiment, pairs in the data set which are sta-
tistically different, or populations which do not overlap
with any other in the data set, (p < 0.05) are indicated
with an asterisk (*).
Results
MUC1/ICAM-1 binding induced signalling is mediated by
Src kinase
We first confirmed that Src kinase is a critical compo-
nent of the MUC1/ICAM-1 signalling axis by siRNA
knockdown of Src in MUC1-CFP transfected HEK 293T
cells. After Src siRNA treatment, we obtained a ~50%
reduction in the levels of Src protein, compared to treat-
ment with Lipofectamine alone or scrambled siRNA
(Figure 2a). We then assayed for calcium oscillations
(Figure 2b) and migration (Figure 2c), and found that
MUC1-CFP cells treated with Lipofectamine-only
respond to ICAM-1 stimulation by generating calcium
oscillations (Figure 2b) and cell migration (Figure 2c),
indicating that the presence of the CFP tail does not
interfere with this response. Non-transfected HEK 293T
cells which have no MUC1 showed no difference in
ICAM-1 binding induced calcium oscillations or migra-
tion with decreased Src. Addition of scrambled siRNA
to the transfected MUC1-CFP cells showed no decrease
in Src levels and levels of ICAM-1 binding induced
events equivalent to the Lipofectamine-only condition
(negative control). However, Src siRNA induced Src
knockdown in HEK 293T cells transfected with MUC1-
CFP resulted in significant decreases in the ICAM-1
binding initiated calcium oscillations (Figure 2b) and
transmigration through an ICAM-1 monolayer (Figure
2c). This establishs Src kinase as an essential mediator
of MUC1/ICAM-1 binding signalling and migration.
MUC1 forms constitutive cytoplasmic domain dimers in
human breast cancer cell lines and transfected HEK 293T
cells
MUC1 positive human breast cancer cell lines MCF-7
and T47D (Figure 3a) and HEK 293T cells transfected
with MUC1-CFP (Figure 3b, panel 1) or the MUC1
splice variant lacking the tandem repeat domain
MUCY-YFP-Fv (Figure 3b, panel 2) were lysed with or
without prior treatment with the membrane permeable
crosslinker DSS. No Fv ligands were added, so only con-
stitutive dimers of the MUCY-YFP-Fv are detectable.
DSS reacts with primary amine containing amino acids
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complexes. It is important to note that DSS only reacts
with lysine residues which are within 11.4 Å of each
other prior to DSS treatment; DSS itself does not induce
complex formation. MUC1-CD contains a membrane-
proximal lysine residue (R
4RK) which would be suscepti-
ble to DSS crosslinking. Western blotting and probing
for MUC1-CD in the cells treated with DSS revealed the
invariable appearance of a new species at exactly double
the molecular weight of the monomeric cytoplasmic
domain, consistent with the presence of a MUC1-CD
homodimer. The appearance of MUC1-CD dimers in
MUCY-YFP-Fv transfectants indicates that the tandem
repeat domain is not responsible for dimerization. This
is not surprising due to the heavy glycosylation and
negative charge of the tandem repeats. We then investi-
gated the contribution of the MUC1 cytoplasmic
domain to dimer formation. HEK 293T cells were co-
transfected with MUCY-YFP-Fv and/or CD8/MUC1
[21], a chimera of CD8 extracellular and transmembrane
domains and MUC1-CD domain, beginning at R
4RK
( F i g u r e1 ) .W h o l ec e l ll y s a t eo fC D 8 / M U C 1( F i g u r e3 c ,
lane 1) shows that this construct appears as a doublet at
approximately 40 kDa in agreement with a publication
describing this construct [21]. MUCY-YFP-Fv runs at
approximately 75 kDa (Figure 3c, lane 2), with another
species migrating at approximately 45 kDa. This species
could be the result of cleavage of the YFP-Fv tag prior
to cell lysis, as MUCY is expected to migrate at this
molecular weight. Dual transfection of CD8/MUC1 and
MUCY-YFP-Fv demonstrates that both these constructs
run at the expected molecular weights when co-
expressed (Figure 3c, lane 3). Immunoprecipitation of
double transfectants with anti-CD8 resulted in the
appearance of MUCY-YFP-Fv on a Western blot (Figure
3c, lane 4), indicating an association between CD8/
MUC1 and MUCY-YFP-Fv. This association is signifi-
cant because the CD8/MUC1 construct only contains
the cytoplasmic portion of MUC1, beginning at R
4RK
and does not contain the membrane proximal C
1QC
motif, fluorescent tags or an Fv domain. Therefore asso-
ciation between these two entities must be due to the
MUC1 cytoplasmic domain. “Protein G + Antibody” and
“Antibody only” lanes are included to identify non-spe-
cific immunoglobulin bands. Taken together, these data
indicate that the cytoplasmic domain of MUC1 self-
associates to form a constitutive homodimer.
MUC1-CD dimerization is independent of membrane-
proximal cysteine residues
Previous publications investigating MUC1 dimerization
have concluded that the membrane-proximal CQC
motif is responsible for disulfide-linked oligomerization,
which results in targeting of MUC1 to the nucleus [18],
and MUC1 mediated resistance to oxidative stress
[19,22,23]. Since the CD8/MUC1-MUCY co-immuno-
precipitation experiments (Figure 3c) found MUC1-CD
association in the absence of a CQC motif in the CD8/
MUC1 partner, we sought to determine if CQC
mediated dimerization was necessary for our observed
constitutive MUC1 dimers in MUC1 full-length trans-
fectants and breast cancer cell lines. Using non-reducing
conditions, which would preserve any disulfide linkages
in Western blotting, there were no bands at a molecular
weight of presumed dimers in 293T MUC1-CFP or
MCF-7 cells (Figure 4a). This suggests that MUC1-CD
Figure 2 Src knockdown and ICAM-1 induced signalling. A. HEK
293T cells without (left panel) or with (right panel) MUC1-CFP
expression were transfected with Scramble or Src targeted siRNA
using Lipofectamine 2000. Following lysis and SDS-PAGE, blots were
probed for Src, or as a control, tubulin. As a control, cells were
treated with Lipofectamine 2000 reagent only (LP only). Cells were
then assayed for ICAM-1 binding induced calcium oscillations (B)o r
migration through an ICAM-1 positive monolayer (C). HEK 293T, LP
only condition was set to one and remaining conditions expressed
as a ratio. Columns represent average oscillation factor (B)o r
average number of migrated cells per five fields (C) from at least
three independent trials; bars, SE. Asterisk indicates pairs in the data
set which are statistically different (p < 0.05).
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mutating both cysteines in the native MUC1-CD CQC
motif to alanines (AQA) and then assaying for dimers
after DSS cross-linking. Note that no Fv ligands were
added so that any dimers detected represent constitutive
or pre-formed dimers. We found that the 293T MUC1-
CFP-Fv (AQA) mutant formed cytoplasmic domain
dimers (Figure 4b). The presence of DSS-stabilized
dimers in the absence of Fv ligands indicates that con-
stitutive MUC1-CD dimers form even when both
cysteines are absent and constitutes conclusive proof
that cellular MUC1-CD dimers are not disulfide linked.
MUC1 cytoplasmic domain dimerization can be disrupted
by an engineered Fv domain and a monomeric ligand
To investigate the importance of MUC1 dimerization in
Src association and ICAM-1 induced signalling, we
manipulated dimerization using a chimeric construct of
MUC1 and a C-terminal Fv domain (ARIAD Pharma-
ceuticals), which is FKBP (FK506 binding protein) with
a F36V mutation, allowing for specific interaction
between the engineered Fv domain and bivalent
(AP20187
D) or monovalent (AP21998
M) ligands. Impor-
tantly, the Fv domain itself does not facilitate dimeriza-
tion of proteins, but following addition of Fv domain
ligands, dimerization status can be manipulated. Pre-
viously, this system has been used to successfully manip-
ulate dimerization of growth factor receptors [24] and G
protein-coupled receptors [25]. Mechanistically, the
bivalent ligand, which contains two Fv-binding domains,
effectively brings two Fv-domain containing proteins
within close proximity - “dimerization”. The monovalent
ligand, which contains one Fv-domain binding domain,
is designed to bind to Fv-domain containing proteins
and sterically inhibit their interaction with other pro-
teins - “disaggregation” or “monomerization” (Figure
5a). MUC1-CD dimers were stabilized after Fv ligand
treatment by addition of the DSS cross-linker prior to
Figure 3 MUC1 dimerization in human breast cancer and transfected cell lines. A. Breast cancer cell lines T47D and MCF-7, or (B) HEK 293T
cells transfected with MUC1 constructs MUC1-CFP and MUCY-YFP-Fv were treated with DSS or no treatment control, lysed, ran on SDS-PAGE
and probed with anti-MUC1-CD. C. HEK 293T cells were transfected with CD8/MUC1 (lane 1) MUCY-YFP-Fv (lane 2), or both (lane 3), lysed, and
double transfectants immunoprecipitated with anti-CD8 (lane 4). Lysates were ran on SDS-PAGE and probed with anti-MUC1-CD. “D” and “M”
indicate expected molecular weights of dimer and monomer, respectively. Whole cell lysates (WCL), PG (Protein G) + Antibody (anti-CD8) and
Antibody only (Anti-CD8) lanes are included as controls.
Figure 4 Covalent bonds and cysteine resides in MUC1
dimerization. A. Breast cancer cell line MCF-7 or HEK 293T cells
transfected with MUC1-CFP were subjected to reducing ("R"; b-
mercaptoethanol added) or non-reducing ("NR"; no b-
mercaptoethanol) conditions, ran on separate SDS-PAGE to prevent
diffusion of b-mercaptoethanol, and probed with anti-MUC1-CD. B.
293T MUC1-CFP-Fv AQA cells were treated with DSS, lysed, ran on
SDS-PAGE, and probed with anti-MUC1-CD. “D” and “M” indicate
expected molecular weights of dimer and monomer, respectively.
Whole cell lysates (WCL) are included as controls.
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Fv cells for one minute with increasing concentrations
of AP20187
D did not increase the quantity of MUC1-
CD dimers above no treatment, while AP21998
M treat-
ment resulted in a dose dependant reduction in MUC1-
CD dimerization (Figure 5b). After treatment with 1 μM
of monomerizing Fv ligand, AP21998
M there was a 60%
reduction in detectable MUC1-CD dimers (Figure 5c).
As a control, 293T MUC1-CFP cells, which lack the Fv
domain, do not show a change in dimer quantity follow-
ing treatment with AP20187
D or AP21998
M (Figure 5d).
Densitometric analysis of the MUC1-CFP dimer band
normalized to monomer band illustrates this observation
further (Figure 5e).
MUC1-CD dimer disruption results in decreased
recruitment of total and active Src kinase
To determine the importance of MUC1-CD dimeriza-
tion in constitutive Src recruitment, 293T MUC1-CFP-
Fv (Figure 6a, b), and, as a control, 293T MUC1-CFP
(Figure 6c, d) cells were treated with increasing concen-
trations of AP20187
D or AP21998
M for one minute and
immunoprecipitated with anti-MUC1-CD. Following
separation on SDS-PAGE, blots were probed with anti-
Src (total) and anti-Src
P416 (active). In the MUC1-CFP-
Fv transfectants, the amount of total and active Src
associated with MUC1-CD decreases in a dose-depen-
dent manner with AP21998
M treatment (Figure 6b,
arrows). Treatment with AP20187
D did not result in a
significant change, and 293T MUC1-CFP cells were
unaffected by Fv ligand treatment.
Densitometric analysis of Src and Src
P416 compared to
MUC1-CD are given in Additional File 1. These data
suggest that MUC1-CD dimers, but not monomers, con-
tain a recruitment, and potentially an activation, motif
for Src kinase.
MUC1-CD dimer disruption results in decreased ICAM-1
binding induced calcium oscillations and cell invasion
To determine if MUC1-CD dimerization is important in
previously observed ICAM-1 binding induced events, we
assayed parental (293T), 293T MUC1-CFP, and 293T
MUC1-CFP-Fv, and 293T MUC1-CFP-Fv (AQA) cells
for ICAM-1 binding induced calcium oscillations, and
invasion through an ICAM-1 positive monolayer after
addition of the Fv ligands 1 μM AP20187
D or 1 μM
AP21998
M and compared this to a no treatment control.
293T MUC1-CFP and 293T MUC1-CFP-Fv cells
responded to treatment with ICAM-1 positive cells, in
the “no treatment” condition, by initiating calcium oscil-
lations (Figure 7a) and increased invasion (Figure 7b) at
levels which were significantly increased compared to
Mock treatment and statistically equivalent, demonstrat-
ing that the addition of the CFP or CFP-Fv tag on the
C-terminus did not affect MUC1 receptor response to
ICAM-1 stimulation. The 293T MUC1-CFP-Fv (AQA)
mutant also exhibited ICAM-1 binding induced calcium
oscillations (Figure 8a) and cell invasion (Figure 8b)
equivalent to the native 293T MUC1-CFP-Fv cells indi-
cating that the CQC motif is not required for ICAM-1
induced signalling events. However, ICAM-1 binding
induced calcium oscillations (Figure 7a) and invasion
(Figure 7b) in 293T MUC1-CFP-Fv cells was signifi-
cantly reduced by treatment with AP21998
M, while pro-
longed treatment with AP20187
D resulted in a
significant increase in cell migration in 293T MUC1-
CFP-Fv cells (Figure 7b). These data indicate that
MUC1-CD dimerization is required for ICAM-1 binding
induced events. Addition of the Fv ligands had no signif-
icant effect on the 293T MUC1-CFP transfectants lack-
ing the Fv domain. As previous reports [19] have
demonstrated that disruption of dimerization using pep-
tides results in cell death, we performed a trypan blue
exclusion assay after treatment with 1 μMA P 2 0 1 8 7
D or
AP21998
M and saw no significant reduction in viability
up to 72 hour exposure (See Additional File 2).
ICAM-1 ligation does not result in increased MUC1-CD
dimerization or disulfide linkage of MUC1-CD dimers
Next, we investigated if ICAM-1 ligation results in a
quantitative increase in MUC1 dimerization, a potential
mechanism for signal initiation. T47D and 293T MUC1-
CFP cells were treated with ICAM-1 transfected NIH
3T3 cells for 10 or 60 seconds prior to DSS treatment.
T h e s et i m ep o i n t sw e r ec h o s e nb e c a u s ep r e v i o u sw o r k
has demonstrated that increased Src and CrkL recruit-
ment, MUC1-CD phosphorylation [6] and calcium oscil-
lations [5] occur within one minute of ICAM-1 ligation.
We found that ICAM-1 ligation did not increase the
quantity of MUC1-CD dimer detected (Figure 9a), sug-
gesting that a qualitative, rather than quantitative,
change in MUC1-CD dimers is responsible for ICAM-1
induced signalling. We then considered the possibility
that ICAM-1 binding triggers disulfide bridge formation,
akin to growth hormone binding to pre-formed growth
hormone receptor dimers [15], but were not able to
detect MUC1-CD dimers in MCF-7 or 293T-MUC1-
CFP cells subjected to reducing or non-reducing condi-
tions after ICAM-1 treatment for 60 seconds (Figure
9b). As a control, the CD8/MUC1 chimera, which is dis-
ulfide linked via the CD8 extracellular region [26,27],
was run under reducing and non-reducing conditions.
The appearance of a disulfide-linked dimer under non-
reducing conditions (Figure 9c) validates our methods.
Discussion
The MUC1 glycoprotein has been implicated in multiple
tumorigenic processes including tumour formation,
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Page 7 of 13Figure 5 Manipulation of MUC1 dimerization using an engineered domain. A. Schematic of the mechanism of dimer formation/disruption
by Fv ligands. B. Treatment of 293T MUC1-CFP-Fv cells with AP20187
D/AP21998
M and DSS. C. Densitometric analysis of dimer bands from B
normalized to total MUC1. “No treatment” control refers to “DSS” only treatment from (B), and it set to one with the remaining conditions
expressed as a ratio. D. Treatment of 293T MUC1-CFP cells with AP20187
D/AP21998
M and DSS. E. Densitometry of MUC1-CFP dimer bands from
D normalized to total MUC1. “No treatment” control refers to “DSS” only treatment from (D) and is set to one with the remaining conditions
expressed as a ratio. “D” and “M” indicate expected molecular weights of dimer and monomer, respectively. Whole cell lysates (WCL) are
included as controls. Asterisk indicates a discrete population that does not overlap with any other population in the data set, p < 0.05.
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Page 8 of 13proliferation, and survival [19,22,28,29]. We are unique
in investigating the role of MUC1 in the motility of
Luminal B breast cancer cell lines, focusing on the bind-
ing of MUC1 to ICAM-1. ICAM-1 is expressed
throughout the migratory track of a metastasizing breast
cancer cell and its role in leukocyte extravasation is well
characterized [30,31]. Although we have previously
shown that MUC1/ICAM-1 ligation induces pro-motility
behaviour [5-7], the mechanism of signal initiation was
unknown. In this report, we show that dimerization of
the MUC1-CD is essential for the ICAM-1 induced
events and that this effect is most likely mediated
through enhanced Src binding.
The signalling capacity of transmembrane proteins
lacking kinase activity is often mediated by associated
non-receptor tyrosine kinases. Here we show that Src
kinase is essential for transmission of the migration
related MUC1/ICAM-1 signal. This is consistent with
the literature on Src inhibition in breast cancer. Even
though transfection of Src alone does not have trans-
forming ability [32], over activity of Src is commonly
associated with breast tumour progression [33] and it
has become a prime target for selective small molecule
inhibitors: Dasatinib (Bristol-Myers Squibb), Bosutinib
(Wyeth) and Saracatinib (AstraZeneca). Others have
published that the MCF-7 luminal B cell line used in
this study shows decreased migration when Src is inhib-
ited [34-36]. This decrease in Src mediated cell migra-
tion is synergistic with concomitant Tamoxifen [37],
associated with upregulation and stabilization of E- cad-
herin/b-catenin mediated intercellular adhesion [36,38],
and decreased activity of the integrin associated kinase,
focal adhesion kinase (FAK) [34,37]. These observations
are consistent with MUC1 involvement in the observed
Src motility pathway. Tamoxifen decreases MUC1
expression [39,40] and down-regulation of MUC1 is
Figure 6 Src and Src
P416 recruitment to MUC1 after manipulation of dimerization. Co-immunoprecipitation with anti-MUC1-CD was
performed on 293T MUC1-CFP-Fv cells (A, B) and MUC1-CFP cells (C, D) after treatment with increasing concentrations of AP20187
D (A, C) or
AP21998
M (B, D). Immunoprecipitates were probed for Src
P416, Src, and anti-MUC1-CD (as a loading control) with stripping of blots between
each probe. Whole cell lysates (WCL), PG (Protein G) + Antibody and Antibody only lanes are included as controls. Densitometric analysis of Src
and Src
P416 compared to MUC1-CD is presented in Additional File 1.
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Page 9 of 13associated with increased E-cadherin/b-catenin complex
formation [41]. Further, MUC1 has been shown to bind
to FAK, possibly transporting Src to FAK forming a
MUC1-Src-FAK complex, and increasing FAK activation
[28]. Thus the additive effect of Tamoxifen, the stabili-
zation of intercellular adhesions and the decreased FAK
activity are logical consequences of the dual inhibition
of MUC1 and Src in the same pathway.
The association between MUC1 and Src is dependent
on the existence of MUC1-CD dimers, indicating that
MUC1-CD dimers adopt a conformation that is permis-
sive Src binding. We have definitive (unpublished) data
demonstrating that a Src-SH3 peptide binds to MUC1
constitutively via the putative SH3 binding domain
R
34XXP
37P
38XXXXR
43. Binding of the Src SH3 domain
has been previously described as a mechanism for par-
tial unfolding of the inactive Src enzyme and can be
associated with Src activation [42] suggesting a mechan-
ism for MUC1-CD dimer activation of Src. In this
regard, it is significant that Src-P
416, which is indicative
of fully active Src, also selectively binds to MUC1-CD
dimers.
Classically, it was believed that surface membrane
receptors existed as monomers until ligand binding
induced dimerization of the receptors, allowing trans-
activation of receptor associated kinases and the trigger-
ing of signal initiating phosphorylation cascades. In
recent years, a new paradigm, typified by the growth
hormone receptor (GHR), has emerged in which recep-
tors exist as pre-formed ligand-independent dimers
[[13], Reviewed in [14]]. Upon ligand binding to the
dimers, structural changes such as cysteine linkage,
association with detergent resistant membrane fractions
or changes in receptor cleavage result in signal initiation
[15-17]. We report here that the MUC1 cytoplasmic
domain exists constitutively as a non-covalently linked
dimer. We present evidence that in the absence of the
transmembrane and extracellular domains, the cytoplas-
mic domain of MUC1 self-associates in a non-cysteine
dependent fashion. It has been proposed that a “self-
aggregation domain” exists in the extracellular stub of
Figure 7 ICAM-1 induced signalling in MUC1 cells after
manipulation of dimerization. HEK 293T (parental), MUC1-CFP,
and MUC1-CFP-Fv cells were assayed for (A) ICAM-1 binding
induced calcium oscillations or (B) migration through an ICAM-1
positive monolayer, after No treatment, 1 uM AP20187
D,o r1u M
AP21998
M. HEK 293T (parental), no treatment condition was set to
one and remaining conditions expressed as a ratio. Columns
represent average oscillation factor (A) or average number of
migrated cells per five fields (B) from at least three independent
trials; bars, SE. Asterisk indicates pairs in the data set which are
statistically different (p < 0.05).
Figure 8 ICAM-1 induced signalling in MUC1-CFP-Fv (AQA)
transfected cells. HEK 293T (parental), MUC1-CFP-Fv and MUC1-
CFP-Fv (AQA) cells were assayed for (A) ICAM-1 binding induced
calcium oscillations and (B) migration through an ICAM-1 positive
monolayer. HEK 293T (parental), mock (no ICAM-1) condition was
set to one and remaining conditions expressed as a ratio. Columns
represent average oscillation factor (A) or average number of
migrated cells per five fields (B) from at least three independent
trials; bars, SE. Asterisk indicates pairs in the data set which are
statistically different (p < 0.05).
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Page 10 of 13MUC1-CD [43], but further studies are required to
address the possibility that functional dimerization in
vivo involves several domains.
In this study, membrane proximal cysteine residues
are not required for dimerization of MUC1-CD, Src
recruitment, or ICAM-1 induced signalling indicating
that disulfide bridge formation is not the ligand-induced
signal initiating event, as has been proposed for GHR.
This is to be expected since, in the reducing environ-
ment of the cytosol, formation and maintenance of dis-
ulfide bonds is unfavourable unless the redox balance is
disrupted [44]. Thus, disulfide linkage of MUC1 dimers
reported by others [18,19], represents an alternative
functional pathway for MUC1-CD dimers, perhaps as a
redox “sensor” [Reviewed in [45]], that is unrelated to
t h eI C A M - 1 / S r cm o t i l i t yp a t h w a yi nt h ep r e s e n ts t u d y .
In this way, cysteine-mediated dimerization of MUC1 in
response to oxidative stress, could initiate a signalling
cascade resulting in the demonstrated nuclear entry and
expression of anti-oxidant enzymes ascribed to cysteine-
linked MUC1-CD dimers [19,22,23].
Rational drug combination has received considerable
interest in recent years [Reviewed in [46]] as it pro-
vides the opportunity for specific, synergistic inhibition
of cell signalling pathways. Initial clinical results using
Src inhibitors as single agents has shown them to be
well-tolerated but have minimal anti-tumour response
in patients [47]. Several Src inhibitors are currently
undergoing testing in clinical trials for use in breast
cancer treatment alone and in combination with other
inhibitors [Reviewed in [48]]. The subset of luminal B
cancers with active Src kinase pathway [49] may be the
ideal target for a combined Tamoxifen and anti-Src
therapy. Our studies suggest that if these could be
combined with an inhibitor of MUC1 dimerization
that cell migration and metastases may be significantly
Figure 9 Covalent dimerization of MUC1 following ICAM-1 binding. A. Breast cancer cell line T47D and 293T-MUC1-CFP cells were
stimulated with NIH-ICAM-1 cells for 10 s or 60 s and treated with DSS, lysed, ran on SDS-PAGE and probed with anti-MUC1-CD. B. Breast
cancer cell line MCF-7 and 293T MUC1-CFP cells were lysed with or without prior treatment with NIH ICAM-1 cells for 60 seconds. Lysates were
subjected to reducing ("R"; b-mercaptoethanol added) or non-reducing ("NR"; no b-mercaptoethanol) conditions, ran on separate SDS-PAGE to
prevent diffusion of b-mercaptoethanol and probed with anti-MUC1-CD. C. 293T CD8/MUC1 cell lysate was run under reducing or non-reducing
conditions, ran on separate SDS-PAGE to prevent diffusion of b-mercaptoethanol and probed with anti-MUC1-CD. “D” and “M” indicate expected
molecular weights of dimer and monomer, respectively. Whole cell lysates (WCL) are included as controls.
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Page 11 of 13decreased, possibly without the toxic effects of classic
chemotherapy.
Conclusion
The MUC1 protein is overexpressed in the majority of
breast cancers and is implicated in breast cancer metas-
tasis. We show here for the first time that MUC1-CD
forms non-covalently linked dimers which are required
for recruitment of Src kinase, and ICAM-1 induced pro-
metastatic events. This is significant because ICAM-1 is
expressed throughout the migratory tract of a metasta-
sizing breast cancer cell. Ligation of MUC1 and ICAM-
1 may represent a mechanism for movement of breast
cancer cells through stromal and endothelial tissues.
Therefore, elucidation of the mechanism of MUC1/
ICAM-1 signalling will reveal potential targets for anti-
metastatic therapies. Our study sheds light on this
mechanism and also demonstrates the need for addi-
tional research to resolve discrepancies in the field.
Additional material
Additional file 1: Densitometry of Src and Src
P416 bands from SDS-
PAGE (Figure 6) normalized to MUC1-CD. Using ImageJ software (NIH),
the Src and Src
P416 bands were analyzed for densitometric intensity, and
values were normalized to the intensity of the corresponding MUC1-CD
band to control for protein loading. The values were then graphed
versus treatment and dose for each cell line.
Additional file 2: Growth curve of MUC1-CFP-Fv cells after
treatment with AP20187
D or AP21998
M. Using Trypan blue exclusion
assay, the number of live cells in a sample were counted daily for 3 days.
The number of live cells in the sample was then extrapolated to estimate
live cells in the population. No significant difference was found in the
populations treated with AP21087
D, AP21998
M, or no treatment control.
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